Anti-ENA antibody profile in hepatitis C patients undergoing hemodialysis

Abstract EN

Infection with hepatitis C virus (HCV) is increasing all over the world, especially among hemodialysis patients.

HCV is one of the major autoantibody inducing viruses, where anti-nuclear antibodies (ANA), anti-smooth muscle antibodies (ASMA), anti-liver kidney micro some antibodies (LKM-1), and rheumatoid factor (RF) have been related to HCV.

Few studies have investigated the presence of anti-extractable nuclear antigens (ENA) antibodies in chronic liver diseases, especially in chronic hepatitis C cases, but none investigated its immunostimulation role in hemodialysis units.

The aim of the study was to assess the prevalence of HCV among chronic kidney disease- Stage 5 (CKD5) patients undergoing hemodialysis and the prevalence of ENA antibodies among them.

Sera of 134 patients with chronic kidney disease undergoing hemodialysis were screened for HCV antibodies and ENA antibodies profile, using ELISA and Immunoblot technique.

41 HCV-positive blood bank donors were used as controls.

Sixty-four (47.7%) of 134 patients undergoing hemodialysis were infected with HCV.

Thirty-three (51.6%) of 64 patients with HCV infection undergoing hemodialysis had anti-ENA antibodies: 9 (27.3%) showed anti-SSA antibodies and 22 (66.7%) had anti-SSB antibodies.

The prevalence of anti-ENA antibodies was significantly higher in the patients with HCV infection, undergoing hemodialysis, compared with both control groups (hepatitis C-positive blood bank donors and hepatitis C-negative patients undergoing hemodialysis).

Seventeen of 33 HCV antibodies-positive males undergoing hemodialysis had anti-ENA antibodies, compared with 16 of 31 females, indicating no sex related difference.

This study emphasizes the high prevalence of HCV infection in our hemodialysis patients, comparable to that of other Middle Eastern countries, but higher than Western ones.

A strong association was observed between anti-HCV positivity and hemodialysis duration, as well as anti-ENA antibody profile.

However, these antibodies were gender independent.